Vimarsana
Biggest News Aggregation in the World

Prospective Registry News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Prospective Registry. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Prospective Registry Today - Breaking & Trending Today

Johnson & Johnson : TREMFYA® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial - Vimarsana News

Johnson & Johnson : TREMFYA® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial

SPRING HOUSE, PENNSYLVANIA, May 31, 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 3b COSMOS clinical trial showing that treatment... | May 31, 2023

EDWARDS ANNOUNCES ONE-YEAR DATA ON TRANSFEMORAL TRANSCATHETER TRICUSPID VALVE REPLACEMENT - Vimarsana News

EDWARDS ANNOUNCES ONE-YEAR DATA ON TRANSFEMORAL TRANSCATHETER TRICUSPID VALVE REPLACEMENT

/PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced that one-year results on patients treated in the single-arm, prospective, global,...

EDWARDS ANNOUNCES ONE-YEAR DATA ON TRANSFEMORAL TRANSCATHETER TRICUSPID VALVE REPLACEMENT - Vimarsana News

EDWARDS ANNOUNCES ONE-YEAR DATA ON TRANSFEMORAL TRANSCATHETER TRICUSPID VALVE REPLACEMENT

/PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced that one-year results on patients treated in the single-arm, prospective, global,...

PreludeDx™ Announces Latest Data on DCISionRT® in Multiple Presentations at the 2022 San Antonio Breast Cancer Symposium - Vimarsana News

PreludeDx™ Announces Latest Data on DCISionRT® in Multiple Presentations at the 2022 San Antonio Breast Cancer Symposium

/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that...

PreludeDx™ to Present DCISionRTÒ and Novel Residual Risk Subtype Prospective Data During Scientific Oral Session at ASTRO 2022 Annual Meeting - Vimarsana News

PreludeDx™ to Present DCISionRTÒ and Novel Residual Risk Subtype Prospective Data During Scientific Oral Session at ASTRO 2022 Annual Meeting

/PRNewswire/ -- Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that...